Welcome to our dedicated page for Avenue Therapeutics SEC filings (Ticker: ATXI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avenue Therapeutics SEC filings document material agreements, governance actions, and the security status of an OTC-quoted specialty pharmaceutical issuer. Recent Form 8-K reports record the exclusive worldwide Duke University license for ATX-04 patents and know-how, the completed sale of Baergic Bio and BAER-101 rights, annual-meeting voting results, and stockholder proposal and director-nomination procedures.
Proxy materials address board elections, auditor ratification, executive compensation tables, and related corporate-governance disclosures. The filings also identify ATXI common stock as registered under Section 12(g) and quoted on OTC Markets.
Avenue Therapeutics, Inc. (ATXI) is asking stockholders to vote at its all-virtual 2025 Annual Meeting on December 30, 2025. Stockholders will elect six directors for one-year terms and ratify the appointment of KPMG LLP as independent registered public accounting firm for the year ending December 31, 2025.
The proxy describes a six‑member board with a majority of independent directors and details audit and compensation committee structures, meeting attendance, and director qualifications. It explains that Fortress Biotech, Inc. beneficially owns more than 50% of the voting power and that Avenue relies on “controlled company” exemptions while still maintaining key independent oversight.
The filing outlines 2023–2024 executive and director compensation, including salaries, bonuses, stock options, and RSUs, as well as a new clawback policy and equity plan capacity of 4,575,701 shares available for future issuance. It also summarizes significant related‑party arrangements with Fortress, the 2022 acquisition and 2025 sale of Baergic, and the termination and transfer of the AJ201 program back to AnnJi, under which Avenue received $1.6 million in other revenue and agreed to a 48‑month non‑compete for competing products in key markets.
Avenue Therapeutics, Inc. has scheduled its 2025 annual meeting of stockholders for December 30, 2025. The exact time and location will be provided in the company’s definitive proxy statement on Schedule 14A to be filed with the SEC.
Stockholders who want their proposals included in the proxy statement under SEC Rule 14a-8 must ensure the company receives them by November 28, 2025 and that they meet all requirements of the Exchange Act and the company’s Second Amended and Restated Bylaws. Proposals or director nominations submitted outside Rule 14a-8, including those using universal proxy rules to solicit support for alternate director nominees, also require written notice to the Corporate Secretary by November 28, 2025 at the company’s Florida headquarters address.
Avenue Therapeutics (ATXI) reported Q3 2025 results showing a net loss of $0.7 million, narrowing from the prior year. For the nine months, net loss was $2.2 million. Operating expenses fell sharply in Q3 to $0.7 million (R&D $0.18 million; G&A $0.55 million) versus $3.2 million a year ago. The company recognized $1.4 million of other revenue year-to-date tied to the AnnJi AJ201 termination and program transfer.
Cash and cash equivalents were $3.709 million at September 30, 2025. Avenue raised $2.094 million earlier in 2025 via its ATM before losing Nasdaq eligibility; the stock now trades on the OTC market. Management disclosed substantial doubt about the ability to continue as a going concern and said additional financing is needed to support a potential Phase 3 safety study of IV tramadol.
Shares outstanding were 3,183,558 as of November 12, 2025. Subsequent to quarter-end, Avenue sold Baergic to Axsome for $0.3 million upfront plus potential milestones and royalties.
Avenue Therapeutics entered a definitive agreement to sell 100% of its majority‑owned subsidiary Baergic Bio to Axsome Therapeutics for an upfront payment of $0.3 million (less transaction fees), plus contingent consideration. Axsome also obtained worldwide commercial, development, and manufacturing rights to BAER‑101, now referred to as AXS‑17, including all available nonclinical and clinical data.
Former Baergic stockholders, including Avenue, are eligible for up to $2.5 million in development and regulatory milestones for the first indication of AXS‑17 and $1.5 million for each additional indication; up to $79 million in commercial sales milestones; and a tiered mid‑to‑high single‑digit royalty on potential global net sales. Avenue expects to receive approximately 74% of all future payments and royalties under the agreement.
In connection with the disposition, Baergic approved equity awards that vest at closing: 443,578 restricted shares to CEO Alexandra MacLean, M.D. and 266,147 restricted shares to CFO/COO David Jin, entitling them to a portion of future payments and royalties tied to the agreement.